TAME Trial: Metformin as Anti-Aging Drug

The Targeting Aging with Metformin (TAME) trial — the first FDA-recognized aging indication trial — is enrolling across 14 US research institutions. The 6-year study targets whether metformin can delay onset of age-related diseases (cardiovascular, cancer, cognitive decline).

• Significance: First trial to treat aging as an indication rather than individual diseases
• Mechanism: AMPK activation → improved mitochondrial function → reduced cellular senescence
• FL Impact: If positive, metformin repurposing could become standard longevity protocol — relevant for family office health planning

Senolytic Therapy: Dasatinib + Quercetin (D+Q)

• D+Q combination selectively eliminates senescent cells ("zombie cells") that drive aging
• Early clinical data shows improved physical function in patients with diabetic kidney disease
• Unity Biotechnology's UBX1325 (senolytic for age-related eye disease) in Phase 2 — key commercialization milestone

KIR-CAR T Cell Therapy Shows Promise (AACR 2026)

A novel KIR-CAR T cell therapy demonstrated safety and dose-dependent efficacy across multiple solid tumor types at AACR 2026. This represents a potential breakthrough in applying CAR-T beyond blood cancers.

• Challenge: Solid tumors create immunosuppressive microenvironments that blunt CAR-T effectiveness
• Innovation: KIR (Killer Immunoglobulin Receptor) platform targets HLA-C — a different mechanism than traditional CD19/BCMA CAR-T
• Universal CAR-T: Allogeneic (off-the-shelf) CAR-T approaches advancing — reduces cost from ~$500K to potentially $50K per treatment

FL Watchlist Coverage

CRISPR Clinical Trials: 2026 Update

Over 80 CRISPR clinical trials are now active worldwide, spanning oncology, rare diseases, and cardiovascular conditions.

• Casgevy (Vertex/CRISPR): First CRISPR therapy approved — for sickle cell disease and beta-thalassemia. Now generating real-world evidence
• Base editing: Beam Therapeutics advancing base-edited CAR-T cells — precision without double-strand breaks
• Prime editing: Next-gen editing with higher precision and fewer off-target effects — preclinical to early clinical
• In vivo delivery: LNP-based CRISPR delivery to liver (Intellia) showing durable gene knockdown — potential for single-dose cures

CRISPR for Familial Hypercholesterolemia

• Verve Therapeutics: Base editing of PCSK9 gene in liver — single infusion could permanently lower LDL
• Phase 1b data expected H2 2026 — if successful, paradigm shift from daily statins to one-time gene edit

iPSC-Derived Cardiomyocytes Show Engraftment

• Induced pluripotent stem cell (iPSC)-derived heart muscle cells demonstrate successful engraftment in primate hearts
• Key milestone toward clinical cardiac regeneration — heart failure affects 64M people globally
• Japan leads clinical translation: Osaka University iPSC heart patch trials ongoing

Multi-Omics Aging Clock

• New multi-omics approach (epigenetic + proteomic + metabolomic) predicts biological age within ±2 years
• Superior to single-modality clocks — enables personalized longevity intervention tracking

Longevity M&A Accelerating

• Big pharma acquiring longevity platforms: Roche/Genentech, AbbVie, Eli Lilly all active
• Diagnostic platform commercialization: liquid biopsy + aging clocks creating new market segment
• FL perspective: Longevity sector transitioning from "science project" to commercial revenue — key inflection for investment allocation